Beta Drugs P/E Ratio
Beta Drugs (BETA) P/E ratio is 50.44 (High), EPS (TTM) ₹40.92, current price ₹2055.20 on NSE vs historical average P/E of 39.87 (100.0th percentile) — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see BETA share price.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
BETA P/E Ratio — Valuation Signal & Historical Context
Beta Drugs P/E 50.44 vs historical average 39.87, range 39.87–39.87 — signal: Overvalued.
- Stock appears overvalued with PE of 50.44, suggesting caution for new investments
- Current PE is 26.5% above historical average
- Trading at discount to sector average PE of 56.83
Beta Drugs P/E Ratio Historical Trend
BETA annual price-to-earnings ratio — 1 years, EPS and year-end price. Current P/E 50.44 vs historical average 39.87. Also explore BETA price trends to track price trends across different timeframes.
BETA Historical P/E Ratio — EPS, Year-End Price & Valuation
Beta Drugs annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 39.87 | 41.49 | ₹1654.00 | NSE | High |
BETA vs Healthcare Peers — P/E Ratio Comparison
Beta Drugs P/E 50.44 vs Healthcare average 56.83, median 31.66 — range 1.99–747.21.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |